Investors

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

Press Releases


Notice: Undefined variable: bgcolor in /home/aldenmaster/dev.fatetherapeutics.com/wp-content/themes/fate-2018/page-templates/ir-news.php on line 42
Mar
16
2017

Fate Therapeutics Reports Fourth Quarter 2016 Financial Results

Read All »

Events & Presentations


Notice: Undefined variable: bgcolor in /home/aldenmaster/dev.fatetherapeutics.com/wp-content/themes/fate-2018/page-templates/ir-news.php on line 100
Mar
16
2017

Fate Therapeutics Q4 2016 and Full Year Earnings Conference Call

Read All »